Insights into the mechanisms of serplulimab: a distinctive anti-PD-1 monoclonal antibody, in combination with a TIGIT or LAG3 inhibitor in preclinical tumor immunotherapy studies by Yizhou Zhang, Ruicheng Wei, Ge Song, Xinyi Yang, Mengli Zhang, Wei Liu, Aiying Xiong, Xuehan Zhang, Qianhao Li, Wan-Jen Yang, Chencheng Han, Rui Liu, Chen Hu, Qingyu Wang, Jun Zhu, Yongqiang Shan

Subjects: Get full text

Efficacy and safety of serplulimab plus nab-paclitaxel in previously treated patients with PD-L1–positive advanced cervical cancer: a phase II, single-arm study by Jusheng An, Xiumin Li, Jing Wang, Lijing Zhu, Ruifang An, Kui Jiang, Yi Huang, Ke Wang, Guiling Li, Chunyan Wang, Jianlin Yuan, Xiaoli Hou, Guiyu Yang, Jing Li, Qingyu Wang, Jun Zhu, Lingying Wu

Subjects: “…serplulimab…”
Get full text

Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carcinoma in China by Shixian Liu, Shixian Liu, Shixian Liu, Nana Jiang, Lei Dou, Lei Dou, Lei Dou, Shunping Li, Shunping Li, Shunping Li

Subjects: Get full text

First-line treatments for extensive-stage small-cell lung cancer with immune checkpoint inhibitors plus chemotherapy: a China-based cost-effectiveness analysis by Lidan Yi, Zhen Zhou, Xiaohui Zeng, Chongqing Tan, Qiao Liu

Subjects: Get full text

Efficacy and safety of different immunotherapies combined with chemotherapy as first-line therapy in patients with small cell lung cancer: a network meta-analysis by Siyao Gong, Qian Li, Xin Yu, Sha Yang

Subjects: Get full text

Cost-effectiveness analysis of serplulimab combination therapy versus chemotherapy alone for patients with extensive-stage small cell lung cancer by Zhiwei Zheng, Hongcai Chen, Hongfu Cai

Subjects: “…serplulimab…”
Get full text

First-line serplulimab plus chemotherapy versus chemotherapy in PD-L1-positive esophageal squamous-cell carcinoma: a cost-effectiveness analysis by Xueyan Liang, Mingyu Meng, Shiran Qin, Xiaoyu Chen, Yan Li

Subjects: “…Serplulimab…”
Get full text

Phase 2 study of serplulimab with the bevacizumab biosimilar HLX04 in the first-line treatment of advanced hepatocellular carcinoma by Zhenggang Ren, Guoliang Shao, Jie Shen, Li Zhang, Xu Zhu, Weijia Fang, Guoping Sun, Yuxian Bai, Jianbing Wu, Lianxin Liu, Yuan Yuan, Jingdong Zhang, Zhen Li, Ling Zhang, Tao Yin, Jincai Wu, Xiaoli Hou, Haoyu Yu, Jing Li, Qingyu Wang, Jun Zhu, Jia Fan, the Serplulimab-HCC Investigators

Subjects: “…Serplulimab…”
Get full text

HLX07 alone or combined with serplulimab, cisplatin and 5‐fluorouracil for advanced esophageal squamous cell carcinoma: A phase 2 study by Yun Liu, Yanfeng Wang, Yanrong Zhu, Tao Wu, Zhenyang Liu, Jin Zhou, Yuan Yuan, Mudan Yang, Bo Liu, Zhenbo Tan, Wu Zhuang, Jiayan Chen, Ning Li, Ying Wang, Xuhui Hu, Lin Wang, Haoyu Yu, Qingyu Wang, Jun Zhu, Jing Huang

Subjects: Get full text

The cost-effectiveness analysis of serplulimab versus regorafenib for treating previously treated unresectable or metastatic microsatellite instability-high or deficient mismatch r... by Yue Ma, Yue Ma, Jiting Zhou, Jiting Zhou, Yuxin Ye, Yuxin Ye, Xintian Wang, Xintian Wang, Aixia Ma, Aixia Ma, Hongchao Li, Hongchao Li

Subjects: Get full text

Pathological complete response to neoadjuvant therapy with serplulimab and chemotherapy in stage IIIB small cell lung cancer: a case report and literature review by Ting Mei, Ting Mei, Ting Wang, Ting Wang, Chuanfen Lei, Dan Jiang, Qinghua Zhou, Qinghua Zhou

Subjects: Get full text

Cost-effectiveness of serplulimab as first-line therapy for extensive-stage small cell lung cancer in China by Guiyuan Xiang, Tingting Jiang, Lanlan Gan, Yuanlin Wu, Ni Zhang, Haiyan Xing, Hui Su, Yanping Li, Dan Peng, Rui Ni, Yao Liu

Subjects: Get full text

Cost-effectiveness of additional serplulimab to chemotherapy in metastatic squamous non-small cell lung cancer patients by Hanrui Zheng, Hanrui Zheng, Ya Zeng, Feng Wen, Feng Wen, Ming Hu

Subjects: Get full text

Cost-effectiveness of analysis serplulimab plus chemotherapy as first-line therapy for PD-L1-positive advanced esophageal squamous cell carcinoma by Hanrui Zheng, Hanrui Zheng, Jiafeng Li, Feng Wen, Feng Wen, Feng Wen, Na Su, Na Su

Subjects: Get full text

A cost-effectiveness analysis of the combination of serplulimab with chemotherapy for advanced esophageal squamous cell carcinoma: insights from the ASTRUM-007 trial by Jiahui Li, Chaoqun Xu, Suyun Yuan

Subjects: Get full text

Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer by Xueyan Liang, Xiaoyu Chen, Xiaoyu Chen, Huijuan Li, Yan Li

Subjects: “…serplulimab…”
Get full text

The effect of liver metastases on clinical efficacy of first‐line programmed death‐1 inhibitor plus chemotherapy in esophageal squamous cell carcinoma: A post hoc analysis of ASTRU... by Jing Gao, Yan Song, Xiaoge Kou, Zhenbo Tan, Shu Zhang, Meili Sun, Jin Zhou, Min Fan, Ming Zhang, Yongxiang Song, Suyi Li, Yuan Yuan, Wu Zhuang, Jingdong Zhang, Li Zhang, Hao Jiang, Kangsheng Gu, Huangyang Ye, Ying Ke, Xiao Qi, Qingyu Wang, Jun Zhu, Jing Huang

Subjects: Get full text

Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: A cost-effectiveness analysis by Youwen Zhu, Kun Liu, Qun Qin, Qun Qin, Hong Zhu, Hong Zhu

Subjects: Get full text

Rare, late onset of immune checkpoint inhibitor-induced type 1 diabetes mellitus in a patient with small-cell lung cancer treated with serplulimab: a case report and review of the ... by Peng Ning, Shilan Liu, Hongyi Cao

Subjects: Get full text